CSL Behring offers many programs and services to the bleeding disorders community, in addition to its range of blood products. Check out this wide variety of resources:

Reimbursement Resources Center

Call 1-800-676-4266 for expert advice and information about insurance matters, including health insurance reimbursement for CSL Behring products.

Patient Assistance Program

This program provides medically necessary therapies to qualified patients who are uninsured, underinsured, or who cannot afford their prescribed therapy.

CSL Behring Assurance ℠

A lapse in insurance coverage can happen—and it can be scary. CSL Behring Assurance helps people who rely on certain CSL Behring products to continue to receive treatment during a lapse in third-party private health insurance.

Important Safety Information

RiaSTAP®, Fibrinogen Concentrate (Human), is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products.

Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving RiaSTAP; weigh the benefits of administration versus the risks of thrombosis.

RiaSTAP is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most serious adverse reactions observed are thrombotic episodes (pulmonary embolism, myocardial infarction, deep vein thrombosis) and anaphylactic reactions. The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache.

Indications

RiaSTAP is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Please see full prescribing information for RiaSTAP.

To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.